Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls for hard caps on prescription drug prices, and his administration continues to push for corporate tax reform that could bring back hundreds of billions in foreign profits currently stored overseas.
The dividend aristocrats AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) appear to be especially well-positioned to benefit from Trump's overtly pro-business stance because of their reliance on high-priced specialty medicines for growth and their considerable overseas cash reserves. With this in mind, let's consider which of these top dividend pharma stocks is the better buy right now.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Stock
With 32 Buy predictions and 1 Sell predictions Johnson & Johnson is one of the favorites of our community.
As a result the target price of 196 € shows a positive potential of 39.72% compared to the current price of 140.28 € for Johnson & Johnson.
